Valuation : Resverlogix Corp.

Market Cap 2.35Cr 1.69Cr 1.46Cr 1.37Cr 1.25Cr 161.43Cr 2.37Cr 16Cr 6.33Cr 82Cr 6.36Cr 6.22Cr 270.94Cr P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 11Cr 7.86Cr 6.79Cr 6.36Cr 5.81Cr 749.74Cr 11Cr 75Cr 29Cr 379.37Cr 30Cr 29Cr 1.26TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.4%
Yield 2024 *
-
Yield 2025 -
1 day-27.42%
1 week-35.55%
Current month-30.66%
1 month-30.66%
3 months-32.28%
6 months-42.77%
Current year-33.29%
1 week 0.05
Extreme 0.0495
0.07
1 month 0.05
Extreme 0.0495
0.08
Current year 0.05
Extreme 0.0492
0.1
1 year 0.05
Extreme 0.0492
0.1
3 years 0.02
Extreme 0.023
0.21
5 years 0.02
Extreme 0.023
0.65
10 years 0.02
Extreme 0.023
4.14
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Change 5-day change 1-year change 3-year change Capi.($)
-27.42%-35.55% - - 2.35Cr
-1.59%-3.35%+64.49%+98.69% 6.95TCr
-1.34%-0.75%+48.56%+90.63% 6.5TCr
-8.37%-12.43%+0.14%-15.42% 2.56TCr
-2.35%-5.75%-12.17%+448.29% 2.59TCr
+0.30%-0.69%+63.18%+11.93% 2.65TCr
-0.96%+10.36%+278.86%+438.78% 2.02TCr
-0.51%+0.23%+33.71%-18.02% 2TCr
-1.91%-4.37%+13.33%+531.29% 1.57TCr
-1.47%+0.68%+43.67%+145.49% 1.35TCr
Average -4.56%-1.93%+59.31%+192.41% 3.13TCr
Weighted average by Cap. -1.93%-1.50%+57.15%+152.82%

Financials

2024 2025
Net sales - -
Net income -76.35L -54.87L -47.42L -44.39L -40.57L -52Cr -76.75L -5.27Cr -2.05Cr -26Cr -2.06Cr -2.02Cr -88Cr -77.67L -55.82L -48.24L -45.15L -41.27L -53Cr -78.07L -5.36Cr -2.09Cr -27Cr -2.1Cr -2.05Cr -89Cr
Net Debt 8.19Cr 5.88Cr 5.08Cr 4.76Cr 4.35Cr 561.43Cr 8.23Cr 57Cr 22Cr 284.08Cr 22Cr 22Cr 942.28Cr 8.58Cr 6.17Cr 5.33Cr 4.99Cr 4.56Cr 588.3Cr 8.62Cr 59Cr 23Cr 297.68Cr 23Cr 23Cr 987.38Cr
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
28/26/28 $0.0495 -27.42% 1,300
27/26/27 $0.0682 -4.88% 11,000